5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Investing.com -- Tango Therapeutics (NASDAQ:TNGX) stock rose 17% on Thursday after the clinical-stage biotechnology company reported positive data from its ongoing Phase 1/2 study of vopimetostat in patients with MTAP-deleted cancers.
The company’s lead PRMT5 inhibitor showed promising results, particularly in second-line MTAP-deleted pancreatic cancer patients, where it demonstrated a median progression-free survival (mPFS) of 7.2 months and an objective response rate (ORR) of 25%. According to the company, this response rate is more than double that observed in historical control studies.
Across all 16 cancer types enrolled in the trial, vopimetostat achieved a 27% ORR in patients with a median follow-up of 9.4 months. The drug also showed strong activity in a histology-agnostic cohort of multiple late-line cancers, with a 49% ORR and mPFS of 9.1 months.
"Current standard of care for patients with advanced pancreatic cancer is multi-agent chemotherapy that confers modest benefit along with side effects that can adversely affect patient quality of life," said Brian Wolpin, Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.
Following FDA consultation, Tango plans to initiate a global, randomized pivotal study in 2026 for patients with MTAP-deleted pancreatic cancer who have received one prior line of therapy. The study will compare vopimetostat at a 250 mg once-daily dose against standard chemotherapy regimens.
The company is also conducting combination studies with Revolution Medicines’ (NASDAQ:RVMD) RAS(ON) inhibitors, with data anticipated in 2026. Separately, Tango announced the pricing of an underwritten offering expected to raise approximately $210 million in gross proceeds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.